ACERAGEN INC (ACGN) Stock Price & Overview
NASDAQ:ACGN • US00445F1093
The current stock price of ACGN is 0.38 USD. Today ACGN is down by -13.83%. In the past month the price decreased by -48.99%.
ACGN Key Statistics
- Market Cap
- 3.2M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
ACGN Stock Performance
ACGN Stock Chart
ACGN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ACGN.
ACGN Earnings
ACGN Forecast & Estimates
7 analysts have analysed ACGN and the average price target is 17.34 USD. This implies a price increase of 4463.16% is expected in the next year compared to the current price of 0.38.
ACGN Groups
Sector & Classification
ACGN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACGN Ownership
ACGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACGN
Company Profile
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Exton, Pennsylvania and currently employs 26 full-time employees. The firm is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
Company Info
IPO: 1996-01-25
ACERAGEN INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA US
Employees: 26
Phone: 14843481600.0
ACERAGEN INC / ACGN FAQ
What does ACERAGEN INC do?
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Exton, Pennsylvania and currently employs 26 full-time employees. The firm is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
What is the current price of ACGN stock?
The current stock price of ACGN is 0.38 USD. The price decreased by -13.83% in the last trading session.
Does ACGN stock pay dividends?
ACGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACGN stock?
ACGN has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
What is the analyst forecast for ACGN stock?
7 analysts have analysed ACGN and the average price target is 17.34 USD. This implies a price increase of 4463.16% is expected in the next year compared to the current price of 0.38.
How many employees does ACERAGEN INC have?
ACERAGEN INC (ACGN) currently has 26 employees.
Can you provide the market cap for ACERAGEN INC?
ACERAGEN INC (ACGN) has a market capitalization of 3.20M USD. This makes ACGN a Nano Cap stock.